# Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects

> **NCT05699070** · PHASE1 · UNKNOWN · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 24 (estimated)

## Conditions studied

- Drug-drug Interaction

## Interventions

- **DRUG:** DWC202211 100mg
- **DRUG:** DWC202212 5mg
- **DRUG:** DWC202211 100mg + DWC202212 5mg

## Key facts

- **NCT ID:** NCT05699070
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-15
- **Primary completion:** 2023-04-24
- **Final completion:** 2023-06-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05699070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05699070, "Drug-drug Interactions Between DWC202211 and DWC202212 in Healthy Subjects". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05699070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*